Savolitinib
Savolitinib is a Chinese-discovered pill that blocks the MET growth signal, approved in China for lung cancers with a MET exon 14 mutation and being tested worldwide with osimertinib.
Overview
Discovered by Hutchmed in Shanghai and partnered with AstraZeneca since 2011, savolitinib received conditional NMPA approval in June 2021 for MET exon 14 skipping NSCLC after platinum chemotherapy or in patients unfit for it, the first selective MET inhibitor approved in China; full approval and first-line use followed. In EGFR-mutant NSCLC with MET-driven resistance to osimertinib, the SAVANNAH and SACHI trials support the savolitinib plus osimertinib combination, with a Chinese approval of the combination in 2025 and the global SAFFRON phase 3 continuing. Also studied in papillary renal cell carcinoma and MET-amplified gastric cancer.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas: how tumours escape and what closes the route · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| China | 2021 | MET exon 14 skipping NSCLC after platinum chemotherapy or unfit for chemotherapy (conditional; later full) |
| China | 2025 | With osimertinib in EGFR-mutant NSCLC with MET amplification after EGFR TKI (SACHI) |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Savolitinib" OR ABSTRACT:"Savolitinib" OR TITLE:"Orpathys" OR ABSTRACT:"Orpathys" OR TITLE:"HMPL-504" OR ABSTRACT:"HMPL-504" OR TITLE:"AZD6094" OR ABSTRACT:"AZD6094" OR TITLE:"volitinib" OR ABSTRACT:"volitinib") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Savolitinib, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductIcotinib
Shares RAS / RAF / MEK / ERK (MAPK), EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
- ProductFurmonertinib
Shares RAS / RAF / MEK / ERK (MAPK), EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
- PersonSamantha Du (Du Ying)
Shares Hutchmed and the tag china.
- ProductAumolertinib
Shares RAS / RAF / MEK / ERK (MAPK), EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
- ProductGarsorasib
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
- TrialAENEAS
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
- InstitutionJiangsu Cancer Hospital
Shares Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag china.
- ProductFulzerasib
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.